AstraZeneca, Daiichi look to broaden Enhertu use again with new study data

  • AstraZeneca and Daiichi Sankyo’s drug Enhertu met the goal of a Phase 3 trial in people whose breast cancer had ultralow levels of an important protein called HER2, a finding that could again expand its use.
  • The companies said Monday that Enhertu treatment was associated with a “statistically significant and clinically meaningful” slowing of tumor progression compared to standard chemotherapy in study participants with a common type of breast cancer that expresses either low or ultralow levels of HER2. The drug’s benefits were consistent between groups, they said.
  • According to the companies, investigators reported an “early trend” toward a survival benefit among those receiving Enhertu, but the data weren’t yet complete enough make a definitive conclusion. The study will continue to assess survival as well as other secondary study measures. AstraZeneca and Daiichi plan to share the results with drug regulators.

Since arriving on the market…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks